Table 4.

Adverse Events Occurring in >2% of All Subjects and in a Greater Percentage of RHB-105 Subjects than Placebo Subjects.

Adverse Event	RHB-105 n = 77	Placebo n = 41	Total N = 118
All subjects with an adverse event	39 (50.6%)	19 (46.3%)	58 (49.2%)
Headache a	12 (15.6%)	4 (9.8%)	16 (13.6%)
Diarrhea	11 (14.3%)	4 (9.8%)	15 (12.7%)
Chromaturia	10 (13.0%)	1 (2.4%)	11 (9.3%)
Rash	4 (5.2%)	0	4 (5.2%)
Nausea	3 (3.9%)	1 (2.4%)	4 (3.4%)
Oropharyngeal pain	3 (3.9%)	0	3 (2.5%)
Blood creatine phosphokinase increase	2 (2.6%)	1 (2.4%)	3 (2.5%)

^a Headache includes headache and migraine.